Hanseatic Management Services Inc. acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 7,620 shares of the biopharmaceutical company’s stock, valued at approximately $608,000.

Other large investors also recently modified their holdings of the company. Pacer Advisors Inc. lifted its stake in Alnylam Pharmaceuticals by 22.0% during the 2nd quarter. Pacer Advisors Inc. now owns 11,610 shares of the biopharmaceutical company’s stock valued at $926,000 after acquiring an additional 2,093 shares in the last quarter. TLP Group LLC bought a new position in Alnylam Pharmaceuticals during the 1st quarter valued at $380,000. Wellington Management Group LLP lifted its stake in Alnylam Pharmaceuticals by 0.3% during the 1st quarter. Wellington Management Group LLP now owns 12,041,179 shares of the biopharmaceutical company’s stock valued at $617,111,000 after acquiring an additional 31,208 shares in the last quarter. Hemenway Trust Co LLC bought a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at $235,000. Finally, BlackRock Inc. lifted its stake in Alnylam Pharmaceuticals by 34,755.2% during the 1st quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock valued at $243,242,000 after acquiring an additional 4,732,617 shares in the last quarter. Institutional investors and hedge funds own 94.25% of the company’s stock.

Several equities analysts have weighed in on ALNY shares. Zacks Investment Research upgraded Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating and set a $88.00 price objective on the stock in a research note on Wednesday, July 12th. Needham & Company LLC restated a “buy” rating and set a $85.00 price objective (down from $98.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 7th. BMO Capital Markets restated an “outperform” rating and set a $99.00 price objective (down from $105.00) on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 6th. ValuEngine cut Alnylam Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 27th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $110.00 price objective (down from $126.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 7th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $93.11.

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) opened at 113.80 on Friday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $31.38 and a 52 week high of $118.40. The company has a 50-day moving average price of $81.14 and a 200-day moving average price of $69.12. The company’s market capitalization is $10.44 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The firm had revenue of $15.93 million during the quarter, compared to the consensus estimate of $23.86 million. During the same period in the prior year, the company posted ($1.05) EPS. The firm’s revenue was up 82.9% compared to the same quarter last year. Analysts predict that Alnylam Pharmaceuticals, Inc. will post ($5.19) earnings per share for the current year.

In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 76,815 shares of the stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total value of $7,681,500.00. Following the transaction, the president now owns 165,399 shares of the company’s stock, valued at $16,539,900. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 4.30% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This news story was posted by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.dailypolitical.com/2017/09/24/hanseatic-management-services-inc-invests-608000-in-alnylam-pharmaceuticals-inc-alny-stock.html.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.